Endocrinpath Liquid
NDC Package 64578-0101-1
Package Information
Endocrinpath (alfalfa, borago officinalis, calcarea carbonica, ceanothus americanus, citricum acidum, fucus vesiculosus, ginkgo biloba, glandula suprarenalis suis, glycyrrhiza glabra, hydrocotyle asiatica, hypothalamus (bovine), kali phosphoricum, pancreas suis, phytolacca decandra, pituitarum posterium (bovine), sarsaparilla (smilax regelii), silicea, syzygium jambolanum, taraxacum officinale, thyroidinum (bovine)) liquids is classified as a
- acidifying activity - [moa] (mechanism of action)
- allergens - [cs]
- anti-coagulant - [epc] (established pharmacologic class)
- calcium chelating activity - [moa] (mechanism of action)
- calculi dissolution agent - [epc] (established pharmacologic class)
- cell-mediated immunity - [pe] (physiologic effect)
- decreased coagulation factor activity - [pe] (physiologic effect)
- dietary proteins - [cs]
- increased histamine release - [pe] (physiologic effect)
- non-standardized food allergenic extract - [epc] (established pharmacologic class)
- non-standardized plant allergenic extract - [epc] (established pharmacologic class)
- plant proteins - [cs]
Identification & Billing
Clinical Specifications
- ALFALFA 15 [hp_X]/mL
- ANHYDROUS CITRIC ACID 15 [hp_X]/mL
- BORAGE 15 [hp_X]/mL
- BOS TAURUS HYPOTHALAMUS 12 [hp_X]/mL
- BOS TAURUS PITUITARY GLAND 12 [hp_X]/mL
- CEANOTHUS AMERICANUS LEAF 4 [hp_X]/mL
- CENTELLA ASIATICA 15 [hp_X]/mL
- FUCUS VESICULOSUS 15 [hp_X]/mL
- GINKGO 15 [hp_X]/mL
- GLYCYRRHIZA GLABRA 15 [hp_X]/mL
- OYSTER SHELL CALCIUM CARBONATE, CRUDE 15 [hp_X]/mL
- PHYTOLACCA AMERICANA ROOT 4 [hp_X]/mL
- POTASSIUM PHOSPHATE, DIBASIC 15 [hp_X]/mL
- SILICON DIOXIDE 12 [hp_X]/mL
- SMILAX ORNATA ROOT 15 [hp_X]/mL
- SUS SCROFA ADRENAL GLAND 9 [hp_X]/mL
- SUS SCROFA PANCREAS 9 [hp_X]/mL
- SYZYGIUM CUMINI SEED 4 [hp_X]/mL
- TARAXACUM OFFICINALE 15 [hp_X]/mL
- THYROID, BOVINE 9 [hp_X]/mL
- Acidifying Activity - [MoA] (Mechanism of Action)
- Allergens - [CS]
- Anti-coagulant - [EPC] (Established Pharmacologic Class)
- Calcium Chelating Activity - [MoA] (Mechanism of Action)
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Dietary Proteins - [CS]
- Increased Histamine Release - [PE] (Physiologic Effect)
- Non-Standardized Food Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Non-Standardized Plant Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Plant Proteins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 64578 - Energetix Corporation
- 64578-0101 - Endocrinpath
- 64578-0101-1 - 59.1 mL in 1 BOTTLE, DROPPER
- 64578-0101 - Endocrinpath
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64578-0101-1 identifies a specific commercial package of 59.1 ml in 1 bottle, dropper of Endocrinpath, a human over the counter drug labeled by Energetix Corporation. This liquid is formulated for oral use and contains alfalfa; anhydrous citric acid; borage; bos taurus hypothalamus; bos taurus pituitary gland; ceanothus americanus leaf; centella asiatica; fucus vesiculosus; ginkgo; glycyrrhiza glabra; oyster shell calcium carbonate, crude; phytolacca americana root; potassium phosphate, dibasic; silicon dioxide; smilax ornata root; sus scrofa adrenal gland; sus scrofa pancreas; syzygium cumini seed; taraxacum officinale; thyroid, bovine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Energetix Corporation on November 20, 2014. The current certification is valid through December 31, 2026.
How is this Energetix Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64578010101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.